Second person dies in anti-obesity drug trial
8th December 2015
A second patient has died in a late-stage trial of the anti-obesity drug beloranib, according to a report in PharmaTimes.
The drug, developed by US biotech Zafgen for the genetic disorder Prader-Willi syndrome, has a chequered history.
US regulators suspended